Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944078 | 1.00 | RORC (0.50) | RORCMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4943009 | 0.93 | NPSR1 (0.46) | RORCMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4943005 | 0.93 | NPSR1 (0.46) | RORCMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4939477 | 0.91 | OXTR (0.47) | RORCMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4943716 | 0.90 | MAPT (0.45) | MAPTKDM4ELMNASMN1; SMN2HPGD | |
| SCHEMBL4943723 | 0.90 | MAPT (0.45) | MAPTKDM4ELMNASMN1; SMN2HPGD | |
| SCHEMBL4943848 | 0.90 | RORC (0.54) | RORCMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4943842 | 0.90 | RORC (0.54) | RORCMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4943415 | 0.86 | NPSR1 (0.49) | RORCMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4943417 | 0.86 | NPSR1 (0.49) | RORCMAPTKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| US-7211601-B2 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-05-01 | — | — | US | disclosed |
| EP-1268418-B1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, PRLHR, NR0B1 | RORC 375/4885MAPT 4816/4885KDM4E 2451/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | RORC 264/4885MAPT 2519/4885KDM4E 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.